Sensius is a contraction of “sense” and the the most commonly used unit for measurement of temperature. A new company in the area of thermotherapy with a high ambition to reveal the true power of the concept that already exists for decades. Planning and quality control of thermotherapy are in the vision of Sensius essential to achieve effective treatment. Protocols, quality assurance, ongoing learning and improvement in the medical practice must be supported by reliable and robust equipment and software. This is the sense that Sensius wants to bring in thermotherapy. We collaborate with Erasmus Medical Center Cancer Clinic and we would be pleased to invite other institutes with a similar sense in thermotherapy to join our circle of innovation.
Paul van den Biggelaar has studied the potential of thermotherapy already for over a decade and is co-founder of Sensius. He got his Master of Science degree in Electrical Engineering at Eindhoven University of Technology with the long term ambition to be engaged with medical technology. Learning the essence of high-tech product development at Lucent Technologies, he broadened his experience as Director of Services at Peek Traffic. In 2005 he joined the executive team of Nucletron as business unit director and later responsible for all product development. During his time at Nucletron he got in touch with RF-based thermotherapy for the first time. In Sensius, Paul performs the role of CEO.
Peter van Paassen studied Industrial Design at the Technical University of Delft. He developed packaging machines and submarines and worked as a consultant for renowned product development companies in Japan, Germany and the Netherlands. Later on in his career he specialized in product innovation and market strategy in healthcare. As interim manager at TNO his task was to bring the medical technology market to the researchers and visa versa. He founded Lavoisier BV with Johannes Wolters in 2009 with the aim of establishing a network of new ventures in medical technology. Peter joined Sensius to support the business development and funding of the company.
Onno Yntema is managing partner at Lavoisier, together with Peter van Paassen. He studied medical biology at the University of Groningen. Onno began his career with the vaccine division of Merck Sharp & Dohme. He was appointed Country Manager in the Netherlands for the joint venture of Pasteur Merieux and MSD. Switching career after more than ten years, he founded PreventCare, organising large-scale vaccination programmes and administering modern medicines from biotechnology in the home situation. In 2010, he successfully sold PreventCare BV. In recent years he has been involved in several projects in health care. In 2014, Onno joined Lavoisier, contributing his medical and market knowledge to help realise the holding’s ambitions.
Rik Kielman studied Business Management in Groningen, the Netherlands. After his study he predominantly held commercial roles in the medtech industry. Rik has great experience in business development and is a result oriented team player. Prior to joining Sensius, he was responsible for business development in a startup medtech company (Gannet). In this role he was responsible for the introduction of an innovative fracture fixation device in major European markets. Rik acquired first contracts with hospitals for clinical use and managed the fringe conditions, such as adaptation to national guidelines and reimbursement. For Sensius, Rik will be the Marketing and Sales director.
Sensius is pleased to be supported by Prof. Gerard van Rhoon, PhD and Maarten Paulides, PhD as advisor Medical Physics.
Prof. Dr. van Rhoon obtained his B.Sc.-degree in Applied Physics at the HTS-Dordrecht, The Netherlands, in 1977. He obtained his PhD degree in 1994 at Delft University of Technology on the thesis “Radiofrequency Hyperthermia System, experimental and clinical assessment of the feasibility of radiofrequency hyperthermia systems for loco-regional deep heating”. He was appointed professor of Physical Aspects of Electromagnetic Fields and Health on 1st February, 2011. His current activities focus mainly on the application of local hyperthermia with the use of non-ionising electromagnetic radiation (“microwaves”). He is strongly involved in the development of the equipment and procedures to enable routine quality assurance for the application of both superficial and deep hyperthermia. Presently he is chairman of the Technical Committee of the European Society for Hyperthermic Oncology (ESHO).’
Maarten Paulides holds an MSc degree in Electrical Engineering (2002) from Eindhoven University of Technology (TU/e) and a cum laude PhD in Health and Medical Physics (2007) from Erasmus University Rotterdam. After obtaining his PhD, Paulides stayed at Erasmus University, as subsequently research associate, Assistant Professor and Associate Professor. In 2018, he returned to TU/e as Associate Professor. In November 2018, he became director of the Center for Care and Cure Technologies Eindhoven (C3Te), part of TU/e. Throughout his career, Paulides has served many times as committee member, visiting researcher and adviser. He currently serves in the Dutch Health Council , ICNRIP/WHO, COST action CA17115 (“MyWave”) and co-founded Sensius.
Michel Rudophie, member of the board of directors of the Lygature foundation, a foundation with a focus on providing medical innovations to people with medical needs all over the world. Rudolphie is also former-director of the Dutch Cancer Society (KWF Kankerbestrijding):
“Sensius is adding value in cancer care by redefining thermotherapy. Through intense focus and real time control Sensius is able to provide a new standard for treating cancer patients and improving quality of life. Sensius fully understand the patient needs and speaks the language of the health care providers. A successful combination benefitting the cancer patient.”
Reender Beks, former CFO of Sapiens former CFO of Forcare, current Partner Vunderink de Vries:
“The Sensius team shares a great passion to defeat cancer and, with a wealth of experience in this field, demonstrates that a novel technology in the form of thermotherapy can significantly contribute to the well-being of patients during the stressful times of radiation and chemo, as many publications show evidence that this therapy can significantly reduce the probability of recurrence of the disease. With a strong value proposition that complements existing treatment modalities, Sensius has the opportunity to vastly expand a market that is yet in its early childhood stage.”
Coen Rasch, professor radiation oncology, chair of the department of Radiation Oncology at Leiden University Medical Center (LUMC), chair of the Dutch Society of Radiation Oncology (NVRO), former chair of the department of Radiation Oncology at Amsterdam Medical Center:
Treatment of Head and Neck cancer urgently needs a potent sensitizer to boost the current therapies and manage the toxicity, as we cannot be satisfied with the outcome today. Sensius’ vision on hyperthermia creates a paradigm shift and propels it into thermotherapy, bringing it to the same level of relevance as radiotherapy and chemotherapy. Their strong clinical orientation makes it usable for clinics to treat patients routinely.
De Lavoisier Group is a fast growing, flexible network of high-tech medical ventures and experienced entrepreneurs. The company is committed to developing emerging medical technologies into new products and successful market introductions. Innovation, acceleration, flexibility, market orientation, internationalization and cooperation are integral parts of the venture strategy. This solid strategy and years of investments in medical business development delivers De Lavoisier Group the skills to support entrepreneurs in building their own ventures in medical technology.
Want to know more? Please do not hesitate to contact us: contact